Revolution Medicines Inc. (RVMD)

The total asset value of Revolution Medicines Inc. (RVMD) stood at $ 1,070 Mln as on 30-Sep-23

The share price of Revolution Medicines Inc. (RVMD) is $24.59 (NASDAQ) as of 08-Dec-2023 16:00 EST. Revolution Medicines Inc. (RVMD) has given a return of -15.93% in the last 3 years.

Revolution Medicines Inc. (RVMD) has a market capitalisation of $ 4,028 Mln as on 08-Dec-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Revolution Medicines Inc. (RVMD) is 4.81 times as on 08-Dec-2023, a 0.89% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Revolution Medicines Inc. (RVMD) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Revolution Medicines Inc. (RVMD) and enter the required number of quantities and click on buy to purchase the shares of Revolution Medicines Inc. (RVMD).

Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

The CEO & director of Dr. Mark A. Goldsmith Ph.D.. is Revolution Medicines Inc. (RVMD), and CFO & Sr. VP is Mr. Jack Anders.

The promoters of Revolution Medicines Inc. (RVMD) have pledged 0% of the total equity as on Sep-23.

Some of the close peers are:

No, TTM profit after tax of Revolution Medicines Inc. (RVMD) was $-223 Mln.